

## Supplementary Table 1.

### Overview of patient characteristics in discovery cohort i.e., UZL-CSI cohort (n=32)

	Characteristics	Results
Age (mean,range)(years)		64.5 (47-85)
Histology(%)	HGSOC	84.4
	LGSOC	6.2
Stage (%)	CCC	6.2
	Mucineus ovariumcarcinoom	3.1
	IC2	3.1
	IIIC	31.2
	IV	9.4
Number of recurrences (%)	IVB	56.3
	0	37.5
	1	25
	2	28.1
	3	3.1
Outcome (%)	>4	6.2
	No evidence of disease	6.2
	Alive with evidence of disease	18.8
	Death of disease	75

## Supplementary Table 2.

**Overview of patient characteristics in validation cohort, i.e., TRANS-IOTA cohort**  
(benign; n=404, borderline; n=90, malignant; n=205)

		<b>Characteristics</b>	<b>Results</b>
Age (mean,range)(years)	benign		48.9 (16-84)
	borderline		48.5 (21-81)
	malignant		58.3 (19-84)
Histology (number ,%)	benign	serous cystadenofibroma	77 (19%)
		teratoma	75(18%)
		serous cystadenoma	59(14.6%)
		mucinous cystadenoma	53(13.1%)
		fibroma	37(9.2%)
		endometrioma	37 (9.2%)
		mucinous cystadenofibroma	14(3.5%)
		functional cyst	7(1.7%)
		struma ovarii	5(1.2%)
		Other	42(10.4%)
	borderline	serous	56(62.2%)
		mucinous gastrointestinal	32(35.5%)
		other	2(2.2%)
	malignant	high grade serous	110 (54%)
		low grade serous	12 (5.8%)
		High grade clear cell high	7 (3.4%)
		Mucinous	6 (2.9%)
Other		70 (34.1%)	
I		75 (87.2%)	
Stage (number,%)	borderline	II	6 (6.9%)
		III	5 (5.8%)
		I	68 (33.7%)
	malignant	II	19 (9.4%)
		II	83 (41.1%)
		IV	32 (15.8%)